Condition: HPV · Sponsor: German Cancer Research Center
First-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers. Investigation of safety and tolerability of ascending doses of PANHPVAX, a vaccine against human papilloma L2 antigens formulated with cdA (adjuvant) as compared to the formulation without cdA.
This description comes directly from the study's public registry record.
Markus Kratzmann, Dr. · +49 (0)6221 56 32014 · markus.kratzmann@nct-heidelberg.de
Always discuss trial participation with your own doctor first.
| University Hospital Department of Clinical Pharmacology and Pharmacoepidemiology | Heidelberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05208710